Sueda Shozo, Sakaue Tomoki
Department of Cardiology, Ehime Niihama Prefectural Hospital Niihama, Japan.
Department of Cardiology, Yawatahama City General Hospital Yawatahama, Japan.
Eur Cardiol. 2024 Aug 21;19:e16. doi: 10.15420/ecr.2022.12. eCollection 2024.
Vasoreactivity testing is used by cardiologists in the diagnosis of coronary spasm endotypes, such as epicardial and microvascular spasm. Intracoronary injection of acetylcholine and ergonovine is defined as a standard class I method according to the Coronary Vasomotion Disorder (COVADIS) Group. Because single vasoreactivity testing may have some clinical limitations in detecting the presence of coronary spasm, supplementary or sequential vasoreactivity testing should be reconsidered. The majority of cardiologists do not consider pseudonegative results when performing these vasoreactivity tests. Vasoreactivity testing may have some limitations when it comes to documenting clinical spasm. In the future, cardiologists around the world should use multiple vasoreactivity tests to verify the presence or absence of epicardial and microvascular spasms in the cardiac catheterisation laboratory.
血管反应性测试被心脏病专家用于诊断冠状动脉痉挛的亚型,如心外膜和微血管痉挛。根据冠状动脉血管运动障碍(COVADIS)小组的定义,冠状动脉内注射乙酰胆碱和麦角新碱是标准的I类方法。由于单次血管反应性测试在检测冠状动脉痉挛的存在时可能存在一些临床局限性,因此应重新考虑补充或序贯血管反应性测试。大多数心脏病专家在进行这些血管反应性测试时不会考虑假阴性结果。在记录临床痉挛方面,血管反应性测试可能存在一些局限性。未来,世界各地的心脏病专家应使用多种血管反应性测试来验证心脏导管实验室中心外膜和微血管痉挛的存在与否。